VC: Vitae leads with $15M

By admin Jul 13, 2005 8:01pm

Vitae leads with $15 million.

VENTURE CAPITAL
COMPANY	AMOUNT/ROUND	LEAD INVESTORS	DESCRIPTION
Vitae Pharmaceuticals Fort Washington, PA	$15 million NA	GlaxoSmithKline	Much of the money will be used to accelerate its multiple programs into the clinic.
Primera Biosystems Providence, RI	$11 million first round	MPM Capital, Burrill and Company	The financing will enable Primera to develop both instrument systems and disease specific diagnostic reagent kits for commercialization.
Panacea Pharmaceuticals Gaithersburg, MD	$7 million third round	Mitsubishi Corporation Life Sciences Venture	Proceeds from the offering will be used to move potential products within the company's HAAH Oncology Program towards clinical-stage development.
Pepscan Systems The Netherlands	$6 million first round	PPM Oost NV	The funds will be used primarily to further expand Pepscan's portfolio of therapeutic vaccines programs in oncology.